argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026

Rhea-AI Summary

argenx (Euronext & Nasdaq: ARGX) will hold an Extraordinary General Meeting of Shareholders at 15:00 CEST on September 17, 2026 at Freshfields LLP, Strawinskylaan 10, Amsterdam. Shareholders may attend in person or by proxy, with e-voting and meeting documentation available via the argenx and ABN AMRO websites.

Market Context

ARGX's 8.56% gain after its July 23 earnings report provides a positive historical comparator for th...

Analysis

ARGX's 8.56% gain after its July 23 earnings report provides a positive historical comparator for this shareholder meeting. The proposed appointments remain subject to votes, while the notice supplies no operating update.

Key Figures

Meeting date: September 17, 2026 Meeting time: 15:00 CEST Voting items: 2 +1 more

4 metrics

Meeting date September 17, 2026 Extraordinary General Meeting

Meeting time 15:00 CEST Extraordinary General Meeting

Voting items 2 Proposed non-executive director appointments

Announcement date August 3, 2026 Article dateline

Historical Context

5 past events · Latest: Jul 27 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 27	Acquisition announcement	Negative	-3.2%	Cash acquisition of Forte Biosciences for $77 per share and approximately $2.2 billion equity value
Jul 23	Earnings report	Positive	+8.6%	Second-quarter product sales reached $1.5 billion, with operating profit of $494 million
Jul 16	Earnings scheduling	Neutral	-0.6%	Company scheduled its half-year results and second-quarter update for July 23
Jun 23	R&D webinar	Neutral	-5.6%	Company announced an autoimmune myositis research and development webinar
Jun 03	Clinical data	Positive	+1.4%	EULAR presentation highlighted sustained benefit and safety across 834 patients

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

ARGX aligned with positive earnings and clinical updates but declined after the acquisition announcement and investor-event notices.

Key Terms

non- executive directors, e-voting system

2 terms

non- executive directors regulatory

"proposed appointments of Mr. Thomas M. Brakel and Mr. Khurem Farooq as non- executive directors"

Non-executive directors are members of a company's board who do not run day-to-day operations; they provide oversight, independent judgment, and advice on strategy, risk, and executive performance. They matter to investors because they act like independent referees or guardians, helping ensure management decisions and financial reporting are scrutinized and aligned with shareholders' long-term interests.

e-voting system technical

"requirements for notification and registration for the meeting and regarding the e-voting system"

An e-voting system is an electronic platform that lets shareholders cast and record votes on corporate matters—such as board elections and mergers—using computers or mobile devices instead of paper ballots. It matters to investors because voting determines who makes key decisions that affect a company’s strategy and value; the system’s ease of use, security and auditability influence turnout, the fairness of outcomes and investors’ confidence in corporate governance, much like online banking replaces paper checks but must be trusted.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

August 3, 2026 – 22:01 PM CEST

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of Shareholders will be held at 15:00 CEST on Thursday, September 17, 2026 at the offices of Freshfields LLP (Netherlands), Strawinskylaan 10, 1077 XZ Amsterdam, the Netherlands.

The shareholders and all other persons entitled to attend the Extraordinary General Meeting are invited to attend. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting and regarding the e-voting system) is available on the argenx website www.argenx.com and on www.abnamro.com/evoting.

Agenda
The two voting items on the agenda will be the proposed appointments of Mr. Thomas M. Brakel and Mr. Khurem Farooq as non- executive directors of the Company’s Board of Directors.
The agenda for the meeting as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection at the argenx offices. A free copy thereof may also be obtained by e-mailing legal@argenx.com. argenx would like to encourage shareholders to use the voting by (electronic) proxy option as referred to in the convocation.

About argenx 
argenx is a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.

Contacts
Media:
Ben Petok
Bpetok@argenx.com

Investors:
Alexandra Roy  
aroy@argenx.com 

FAQ

When is the argenx (ARGX) Extraordinary General Meeting of Shareholders in 2026?

The argenx Extraordinary General Meeting of Shareholders is scheduled for 15:00 CEST on Thursday, September 17, 2026. According to argenx, the meeting will take place in Amsterdam and will cover two proposed non-executive director appointments.

Where will the argenx (ARGX) Extraordinary General Meeting on September 17, 2026 be held?

The argenx Extraordinary General Meeting will be held at Freshfields LLP (Netherlands), Strawinskylaan 10, 1077 XZ Amsterdam. According to argenx, shareholders and other entitled persons are invited to attend at this location or participate via proxy and e-voting options.

What are the main agenda items for the argenx (ARGX) Extraordinary General Meeting in September 2026?

The main agenda items are the proposed appointments of Mr. Thomas M. Brakel and Mr. Khurem Farooq as non-executive directors. According to argenx, these are the two voting items listed for shareholder decision at the Extraordinary General Meeting.

How can argenx (ARGX) shareholders vote or give a proxy for the September 17, 2026 EGM?

Shareholders can vote by attending in person or using an (electronic) proxy and e-voting system. According to argenx, detailed instructions on notification, registration, and proxy voting are provided in the convocation on its website and on ABN AMRO’s e-voting portal.

Where can investors find the agenda and documents for the 2026 argenx (ARGX) Extraordinary General Meeting?

The agenda and all ancillary documents are available via the argenx website and for inspection at argenx offices. According to argenx, shareholders may also request a free copy of the materials by emailing legal@argenx.com before the Extraordinary General Meeting.

Are non-shareholders allowed to attend the argenx (ARGX) Extraordinary General Meeting in September 2026?

Attendance is open to shareholders and other persons entitled to attend under applicable rules. According to argenx, eligibility details and any specific requirements are outlined in the formal notice of convocation available on its website and through the ABN AMRO e-voting portal.